Device Trial Radar · NCT06939907
Clinical Trial to Evaluate the Efficacy and Safety of Nexpowder™ for Diverticular Bleeding in the Lower Gastrointestinal Tract
Last checked: Nov 19, 2026Latest source record: Apr 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jun 2025
Primary completion
Jun 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- Next Biomedical Co., Ltd.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 23, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Clinical Trial to Evaluate the Efficacy and Safety of Nexpowder™ for Diverticular Bleeding in the Lower Gastrointestinal Tract
Conditions
- Lower Gastrointestinal Bleeding
- Diverticular Bleeding
Interventions
Nexpowder™Device
Nexpowder™ hemostatic powder
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rebleeding rateTime frame: 30 days post treatment
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Chungbuk National University Hospital
Cheongju-si, South Korea
Chungnam National University Hospital
Daejeon, South Korea
Chosun University Hospital
Gwangju, South Korea
3 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.